148 related articles for article (PubMed ID: 10623624)
21. Time-dependent inactivation of aromatase by 6-alkylandrosta-1,4-diene-3,17-diones. Effects of length and configuration of 6-alkyl group.
Numazawa M; Oshibe M; Yamaguchi S; Tachibana M
J Med Chem; 1996 Mar; 39(5):1033-8. PubMed ID: 8676338
[TBL] [Abstract][Full Text] [Related]
22. Combining computational and biochemical studies for a rationale on the anti-aromatase activity of natural polyphenols.
Neves MA; Dinis TC; Colombo G; Sá e Melo ML
ChemMedChem; 2007 Dec; 2(12):1750-62. PubMed ID: 17910019
[TBL] [Abstract][Full Text] [Related]
23. 6beta,19-Bridged androstenedione analogs as aromatase inhibitors.
Komatsu S; Yaguchi A; Yamashita K; Nagaoka M; Numazawa M
Steroids; 2009 Nov; 74(12):884-9. PubMed ID: 19524602
[TBL] [Abstract][Full Text] [Related]
24. Structure-activity relationships of a new family of steroidal aromatase inhibitors. 1. Synthesis and evaluation of a series of analogs related to 19-[(methylthio)methyl]androstenedione (RU54115).
Lesuisse D; Gourvest JF; Benslimane O; Canu F; Delaisi C; Doucet B; Hartmann C; Lefrançois JM; Tric B; Mansuy D; Philibert D; Teutsch G
J Med Chem; 1996 Feb; 39(3):757-72. PubMed ID: 8576919
[TBL] [Abstract][Full Text] [Related]
25. A novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site.
Katz BA; Elrod K; Luong C; Rice MJ; Mackman RL; Sprengeler PA; Spencer J; Hataye J; Janc J; Link J; Litvak J; Rai R; Rice K; Sideris S; Verner E; Young W
J Mol Biol; 2001 Apr; 307(5):1451-86. PubMed ID: 11292354
[TBL] [Abstract][Full Text] [Related]
26. Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19).
Muftuoglu Y; Mustata G
Bioorg Med Chem Lett; 2010 May; 20(10):3050-64. PubMed ID: 20413308
[TBL] [Abstract][Full Text] [Related]
27. Crystallographic and molecular modeling studies on 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione and its butyl analogue, inhibitors of mammalian aromatase. Comparison with natural substrates: prediction of enantioselectivity for N-alkyl derivatives.
Laughton CA; McKenna R; Neidle S; Jarman M; McCague R; Rowlands MG
J Med Chem; 1990 Sep; 33(9):2673-9. PubMed ID: 2391706
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and biological evaluation of 4-imidazolylflavans as nonsteroidal aromatase inhibitors.
Pouget C; Yahiaoui S; Fagnere C; Habrioux G; Chulia AJ
Bioorg Chem; 2004 Dec; 32(6):494-503. PubMed ID: 15530990
[TBL] [Abstract][Full Text] [Related]
29. Aromatase inhibitors--mechanisms for non-steroidal inhibitors.
Vanden Bossche HV; Moereels H; Koymans LM
Breast Cancer Res Treat; 1994; 30(1):43-55. PubMed ID: 7949204
[TBL] [Abstract][Full Text] [Related]
30. Aromatase inhibitors: new endocrine treatment of breast cancer.
Brueggemeier RW
Semin Reprod Med; 2004 Feb; 22(1):31-43. PubMed ID: 15083379
[TBL] [Abstract][Full Text] [Related]
31. Synthesis, evaluation and QSAR studies of highly potent aromatase inhibitors of the piperidinedione type.
Baston E; Klein CD; Grimminger W; Hebecker N; Hartmann RW
Anticancer Drug Des; 2001 Feb; 16(1):37-47. PubMed ID: 11762643
[TBL] [Abstract][Full Text] [Related]
32. Molecular basis for the interaction of four different classes of substrates and inhibitors with human aromatase.
Hong Y; Cho M; Yuan YC; Chen S
Biochem Pharmacol; 2008 Mar; 75(5):1161-9. PubMed ID: 18184606
[TBL] [Abstract][Full Text] [Related]
33. Potent CYP19 (aromatase) 1-[(benzofuran-2-yl)(phenylmethyl)pyridine, -imidazole, and -triazole inhibitors: synthesis and biological evaluation.
Saberi MR; Vinh TK; Yee SW; Griffiths BJ; Evans PJ; Simons C
J Med Chem; 2006 Feb; 49(3):1016-22. PubMed ID: 16451067
[TBL] [Abstract][Full Text] [Related]
34. 2-difluoromethyloestrone 3-O-sulphamate, a highly potent steroid sulphatase inhibitor.
Reed JE; Woo LW; Robinson JJ; Leblond B; Leese MP; Purohit A; Reed MJ; Potter BV
Biochem Biophys Res Commun; 2004 Apr; 317(1):169-75. PubMed ID: 15047163
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of the racemate and the enantiomers of a new highly active and selective aromatase inhibitor of the aminoglutethimide type.
Hartmann RW; Grün G; Bartz U; Palzer M
J Steroid Biochem Mol Biol; 1992 Dec; 43(7):641-8. PubMed ID: 1472456
[TBL] [Abstract][Full Text] [Related]
36. Lead optimization providing a series of flavone derivatives as potent nonsteroidal inhibitors of the cytochrome P450 aromatase enzyme.
Gobbi S; Cavalli A; Rampa A; Belluti F; Piazzi L; Paluszcak A; Hartmann RW; Recanatini M; Bisi A
J Med Chem; 2006 Jul; 49(15):4777-80. PubMed ID: 16854084
[TBL] [Abstract][Full Text] [Related]
37. The derivation of a potential transition state for the reduction reaction catalysed by 17beta-hydroxysteroid dehydrogenase--an approximate representation of its active site for use in drug design and discovery.
Owen CP; Ahmed S
Biochem Biophys Res Commun; 2004 May; 318(1):131-4. PubMed ID: 15110763
[TBL] [Abstract][Full Text] [Related]
38. 6 beta-Propynyl-substituted steroids: mechanism-based enzyme-activated irreversible inhibitors of aromatase.
Akkani A; Paterlini G; Gleason WB; Ojala WH; Abul-Hajj YJ
J Med Chem; 1997 Sep; 40(20):3263-70. PubMed ID: 9379446
[TBL] [Abstract][Full Text] [Related]
39. The strength of dehalogenase-substrate hydrogen bonding correlates with the rate of Meisenheimer intermediate formation.
Dong J; Lu X; Wei Y; Luo L; Dunaway-Mariano D; Carey PR
Biochemistry; 2003 Aug; 42(31):9482-90. PubMed ID: 12899635
[TBL] [Abstract][Full Text] [Related]
40. Evidence that serine 304 is not a key ligand-binding residue in the active site of cytochrome P450 2D6.
Ellis SW; Hayhurst GP; Lightfoot T; Smith G; Harlow J; Rowland-Yeo K; Larsson C; Mahling J; Lim CK; Wolf CR; Blackburn MG; Lennard MS; Tucker GT
Biochem J; 2000 Feb; 345 Pt 3(Pt 3):565-71. PubMed ID: 10642515
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
